TransMedics Group, Inc. Financials

Market Capitalization $4.32 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	89.92
Forward PE	77.39
Price to Sales TTM	$8.85
Price to Book MRQ	$16.22
Enterprise to Revenue	9.71
Enterprise to EBITDA	63.99

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	10.03%
Operating Margin	19.12%
Return on Assets TTM	4.21%
Return on Equity TTM	22.99%

Income Statement

Revenue TTM	$488,227,008
Revenue per Share TTM	$14.59
Quarterly Revenue Growth	48.20%
Gross Profit TTM	$290,347,008
EBITDA	$85,428,000
Net Income to Common TTM	$48,949,000
Diluted EPS TTM	$1.42
Quarterly Earnings Growth YoY	110.60%

Balance Sheet

Total Cash MRQ	$310,143,008
Total Cash per Share MRQ	$9.17
Total Debt MRQ	$
Total Debt to Equity MRQ	194.67
Current Ratio MRQ	9.10
Book Value per Share MRQ	$7.87

Cash Flow

Operating Cash Flow TTM	$49,383,000
Levered Free Cash Flow TTM	$-84,812,248

TMDX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	33,617,972
Float Shares	32,830,616
Avg 10 Volume	896,235
Avg 30 Volume	None
Shares Short	7,860,937
Short Ratio	9.46
Short % of Shares	40.14%
% Held by Insiders	3.03%
% Held by Institutions	121.56%

Stock Price Summary

Beta	2.08
Fifty Two Week Low	$55.00
Fifty Two Week High	$177.37
Fifty Two Week Change	-17.93%
Day 50 MA	$119.61
Day 200 MA	$95.10

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date